Alberta confirmed a rare case of blood clots in a patient who received the Oxford-AstraZeneca vaccine, the state’s chief healthcare officer, announced on Saturday.
Dr. Dina Hinsho said that a male patient recovering in his 60s would mark a second Canadian case of vaccine-induced immune thrombocytopenia, or thrombocytopenia known as VITT.
She said the incident did not change the state’s risk assessment of vaccines.
“I continue to recommend AstraZeneca to all people over the age of 55 and recommend that all Alberts be vaccinated as soon as possible,” she said in a statement. “It’s the best way to protect your health and the health of the people around you.”
To date, more than 700,000 doses of AstraZeneca have been administered throughout Canada.
According to Hinsho, the global frequency of VITT is estimated to be about 1 in 100,000 to 250,000 doses.
In a complete comparison, she said that Albertan, 55 and older, diagnosed with COVID-19, had a one-200th chance of dying from the infection.
A woman in Quebec was the first to develop a blood clot in Canada after being vaccinated against AstraZeneca.
According to the Public Health Agency of Canada, the woman received a vaccine produced at the Serum Institute of India, known as Cobishield, and was recovering at home.
“All side effects are disappointing, but it’s important to remember that these blood clots are very rare and this vaccine helps prevent a much higher risk from COVID-19 infection,” Hinshaw said. Stated.